imvigor011: atezolizumab for ctdna-positive patients with high-risk muscle invasive bladder cancer
Published 2 years ago • 223 plays • Length 4:43Download video MP4
Download video MP3
Similar videos
-
2:36
imvigor010 & imvigor011: ctdna as a response biomarker for adjuvant atezolizumab in high-risk mibc
-
8:22
asco: adjuvant atezolizumab for high-risk muscle-invasive bladder cancer
-
1:17
exploring ctdna in muscle-invasive bladder cancer: future applications and current limitations
-
2:43
atezolizumab to help survival in bladder cancer patients with ctdna positivity
-
2:35
genomic determinants of response to tmt for patients with muscle-invasive bladder cancer
-
2:52
pd-l1 and tmb as biomarkers in the imvigor211 trial of atezolizumab vs. chemo for bladder cancer
-
3:42
imbrave050: adjuvant atezolizumab with bevacizumab in high-risk hcc
-
19:21
immunotherapy for muscle invasive bladder cancer
-
23:44
a review of aua/suo/astro guidelines for muscle invasive bladder cancer (mibc)
-
0:57
biomarkers for muscle-invasive bladder cancer in the ambassador trial
-
0:34
cfdna for mrd detection in non-muscle invasive bladder cancer
-
4:20
imvigor130 data: atezolizumab alone or with chemo upfront for bladder cancer
-
1:36
liquid biopsies and tumor-informed ctdna profiling in metastatic urothelial carcinoma
-
1:52
can atezolizumab succeed where bcg fails in bladder cancer?
-
5:03
atezolizumab with ebrt for bladder preservation in mibc
-
3:43
imvigor010: atezolizumab for uc
-
2:04
unmet need in bladder cancer
-
0:16
imvigor 210 results in metastatic urothelial carcinoma
-
0:58
real-world monitoring of circulating tumor dna to predict cancer recurrence